Triveni Bio Launches with $92M Series A Financing
Company aims to develop functional antibodies for the treatment of immunological & inflammatory disorders.
Triveni Bio, a biotech company focused on pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management. According to a company press release, the financing will support the advancement of TRIV-509, its lead antibody program, for the treatment of atopic dermatitis, asthma, and other I&I indications.
"We are grateful for the support of our investors who understand the upfront benefit of leveraging human genetics – especially learnings from rare Mendelian forms of disease – to expose novel drug targets relevant across multiple common diseases with shared traits," said Vishal Patel, PhD, CEO, Triveni Bio. "Triveni Bio is at a key inflection point as we transition into a clinical stage company with a compelling therapeutic pipeline and talented team."
Reference: Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders. PR Newswire. October 26, 2023. Accessed October 26, 2023. https://www.prnewswire.com/news-releases/triveni-bio-launches-with-92-million-series-a-financing-to-advance-genetics-informed-precision-medicines-for-the-treatment-of-immunological-and-inflammatory-ii-disorders-301967602.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
